Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of HRAIN01 CD19 CAR-T in R/R B-cell ALL
NCT03798509Phase 1Unknown
- Sponsor
- Shanghai HRAIN Biotechnology
- Start
- Mar 2019
- Primary completion
- Jan 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRAIN01 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Shanghai HRAIN Biotechnology. Primary endpoint: Dose Limiting Toxicity. Status: unknown.
02
Drugs
HRAIN01
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03798509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03798509.